安徽医科大学学报Issue(2)：160-163,4.
耐吉非替尼人非小细胞肺癌细胞株的建立及其耐药机制
Establishment of a gefitinib-resistant human non-small cell lung cancer cell line and investigation of its resistance mechanism
摘要
Abstract
Objective To establish PC9 cell line resistant to gefitinib and investigate its possible resistant mecha-nisms. Methods Human gefitinib-resistant non-small cell lung cancer cell line PC9/Gefitinib was established by gradually increasing concentration of gefitinib from its parental cell line PC9 in vitro. The IC50 value and resistance index( RI) of gefitinib were determined by MTT. MTT was also used to evaluate the sensitivity of docetaxel, peme-trexed and gemcitabine in PC9/Gefitinib cell line. Cell cycles were assayed by flow cytometry. Western blot analy-sis was used to investigate the expression of p-AKT and Bcl-2 . Results Gefitinib-resistant human non-small cell lung cancer PC9/Gefitinib had been established successfully, with the RI being 106.95. Compared to PC9 cells, PC9/Gefitinib cells had an increased sensitivity to docetaxel and showed certain resistance to pemetrexed. The cell cycles of G0/G1 period and S period had a significant difference between these two cell lines(P<0.05),the G2/M period change was not obvious. Compared with its parental PC9 cell line, the expression of Bcl-2 was significantly increased while the levels of p-AKT were obviously decreased in PC9/Gefitinib cell line. Conclusion Human ge-fitinib-resistant non-small cell lung cancer cell line PC9/Gefitinib is established successfully, and we speculate that the activation of Bcl-2 and decrease of p-AKT expression appeared to be associated with resistance to gefitinib.关键词
吉非替尼/非小细胞肺癌/耐药Key words
gefitinib/non-small cell lung cancer/drug-resistant分类
医药卫生引用本文复制引用
吴敏,袁媛,潘跃银,张颖..耐吉非替尼人非小细胞肺癌细胞株的建立及其耐药机制[J].安徽医科大学学报,2014,(2):160-163,4.基金项目
安徽高校省级自然科学研究项目(编号:KJ2012A157) （编号:KJ2012A157）
